Dato Kim Tan is Chairman of SpringHill Management, a private fund management company specialising in biotech and social venture capital investments. He has been a pioneer of social impact investing for over 20 years and is a partner of several social impact funds including Inqo Investments (South Africa), Novastar Ventures (Kenya) and Garden Impact Investment (Singapore). He is an advisor to Johnson & Johnson Impact Ventures.
He is the co-founder of the Transformational Business Network and a trustee of the John Templeton Foundation, Templeton Religion Trust and the Centre for Enterprise, Markets & Ethics (Oxford). He was the founder chairman of NCI Cancer Hospital (Malaysia) and the inventor of the sheep monoclonal antibodies. He developed the first rapid tests for Salmonella in chickens and for atrazine pesticide in drinking water.
He is a Pro-Chancellor of Surrey University (UK) and a Fellow of the Royal Society of Medicine (UK). He was the former Chairman of the Surrey & Hants Innovation Growth Team, former board member of the APEC Life Science Innovation Forum and the Saracens Rugby Club.
He has a PhD in Biochemistry and 3 post-doctoral fellowships from the Medical Research Council (UK). He was the recipient of the Guildford Roll of Honour (2014) and the UK Beacon Award for Impact Investment (2017).